Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

GPhC: Former trans hormone-dispensing pharmacy must ‘rectify failures’

The GPhC has told an online pharmacy that recently halted the dispensing of hormone scripts from a transgender clinic that it must “rectify failures”.

Online pharmacy Clear Chemist – which is based in Aintree, Merseyside and is owned by RB Healthcare Ltd – announced earlier this month (October 9) that it had decided to stop fulfilling hormone prescriptions it received from digital transgender clinic GenderGP, owned by Hong-Kong-based company Harland International.

The pharmacy said at the time that its decision, which it took “with a heavy heart”, had not been enforced by the General Pharmaceutical Council (GPhC), which was “looking into concerns raised about Clear Chemist as a matter of urgency” in the wake of a media backlash.

In a statement published yesterday (October 28), GPhC CEO Duncan Rudkin said the regulator had “not asked the pharmacy to stop supplying medicines to patients undergoing treatment for gender dysphoria”.

However, following an “intelligence-led inspection” on October 5, the GPhC has issued an improvement notice to Clear Chemist, asking the pharmacy to “rectify failures” that its inspectors identified earlier this month.

Standards not met

The GPhC inspectors found “serious system-wide failures in the governance and management of risk at the pharmacy”, the GPhC said.

“The inspectors took into account the volume and type of medicines supplied, the age range and potential vulnerability of the patients, and the additional risks of working with prescribers based in the EEA and working outside UK regulatory oversight,” the GPhC  wrote in the enforcement notice, which has been effective since last week (October 21).

The regulator said the pharmacy should put in place a comprehensive risk assessment for the services it provides “at a distance” and “update [their] safeguarding policy and procedures”. The date for compliance set by the GPhC is November 18.

“Factual inaccuracies and erroneous assumptions”

Clear Chemist told C+D yesterday that it disputes the GPhC notice and that it is “increasingly concerned that it contains a number of factual inaccuracies and erroneous assumptions”.

“We have written to the GPhC providing examples of these inaccuracies and evidence supporting our position in that standards are being met,” it added.

Clear Chemist said the GPhC was aware of the services the pharmacy used to offer to some of its patients and that its collaboration with transgender clinic GenderGP was known to the regulator through a previous inspection.

The pharmacy said that it was found to meet “all the necessary standards” at that inspection.

The regulator confirmed to C+D that ClearChemist met the standards for registered when it was inspected in March 2019.

“We have made the GPhC aware we are taking legal advice on our current position as the improvement notice is subject to appeal,” Clear Chemist said.

The Times and the BBC revealed earlier this month (October 6) that parents of transgender children can obtain puberty blockers and sex hormones on prescription from GenderGP. Until October 9, parents could place orders for these medicines with Clear Chemist.

The Times article suggested that the service offered by the two providers allowed people to circumvent some safeguards that are in place to protect children who receive the medicines through NHS routes.

What do you make of the GPhC's decision?

Related Content

Topics

         
Pharmacy Manager / Pharmacist
Guernsey
£70,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD006812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel